Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas

BACKGROUND: ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC. The purpose of this study was to elucidate the underlying molecular mechanism of this interaction and the be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Zoi, Ilianna, Karamouzis, Michalis V., Xingi, Evangelia, Sarantis, Panagiotis, Thomaidou, Dimitra, Lembessis, Panayiotis, Theocharis, Stamatios, Papavassiliou, Athanasios G.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6892243/
https://ncbi.nlm.nih.gov/pubmed/31796128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1226-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados